Patents by Inventor Govindan Subramanian
Govindan Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399388Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: December 9, 2022Publication date: December 14, 2023Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20230071039Abstract: The invention describes novel serotonin c5-HT2B receptor antagonists of Formula (1), and pharmaceutically acceptable salts thereof; wherein Ring A, L, X, X?, R3, R4, m and n are as defined herein. Also described are compositions comprising a Formula (1) compound, or a pharmaceutically acceptable salt thereof; and methods of using the compounds, or a pharmaceutically acceptable salt thereof, for the treatment of myxomatous mitral valve disease (MMVD), congestive heart failure (CHF) and/or asymptomatic heart failure in animals, preferably is a canine.Type: ApplicationFiled: July 22, 2022Publication date: March 9, 2023Inventors: Richard A. Ewin, Ashley E. Fenwick, Govindan Subramanian
-
Publication number: 20220162183Abstract: The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably canine.Type: ApplicationFiled: March 26, 2020Publication date: May 26, 2022Inventors: Richard Andrew Ewin, Govindan Subramanian, Jinxia (Nancy) Deng
-
Publication number: 20200115441Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: September 24, 2019Publication date: April 16, 2020Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 10570129Abstract: The present invention provides Formula (1) compounds that are gamma-carbolines, Formula (1) wherein R1a, R1b, R1c, R1d, R2, R3, and “-” are as defined herein; veterinary acceptable salts thereof, and stereoisomers thereof, which act as parasiticides, in particular, endoparasiticides.Type: GrantFiled: June 10, 2016Date of Patent: February 25, 2020Assignee: Zoetis Services LLCInventors: Govindan Subramanian, Michael P. Curtis, Jinxia (Nancy) Deng, Richard Andrew Ewin, Christopher Scott Knauer, Graham M. Kyne, Tomasz Respondek, Susan Mary Kult Sheehan, John Adam Wendt
-
Publication number: 20200031822Abstract: The present invention provides Formula (1) compounds that are gamma-carbolines, Formula (1) wherein R1 a, R1 b, R1 c, R1d, R2, R3, and “-” are as defined herein; veterinary acceptable salts thereof, and stereoisomers thereof, which act as parasiticides, in particular, endoperasiticides.Type: ApplicationFiled: June 10, 2016Publication date: January 30, 2020Applicant: Zoetis Services LLCInventors: Govindan SUBRAMANIAN, Michael P. CURTIS, Jinxia (Nancy) DENG, Richard Andrew EWIN, Christopher Scott KNAUER, Graham M. KYNE, Tomasz RESPONDEK, Susan Mary Kult SHEEHAN, John Adam WENDT
-
Patent number: 10465002Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: December 18, 2017Date of Patent: November 5, 2019Assignee: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20180222967Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: December 18, 2017Publication date: August 9, 2018Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 9879079Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: May 25, 2016Date of Patent: January 30, 2018Assignee: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20160368976Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kanidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kanidin activity or detect Kallidin or des-Arg10-Kanidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: May 25, 2016Publication date: December 22, 2016Applicant: SanofiInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 9376494Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: March 15, 2013Date of Patent: June 28, 2016Assignee: SanofiInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20150050270Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: March 15, 2013Publication date: February 19, 2015Applicant: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritzker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 8404731Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.Type: GrantFiled: January 11, 2010Date of Patent: March 26, 2013Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
-
Patent number: 8377983Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.Type: GrantFiled: February 10, 2010Date of Patent: February 19, 2013Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu
-
Patent number: 8263634Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: November 9, 2010Date of Patent: September 11, 2012Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
-
Publication number: 20120196906Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.Type: ApplicationFiled: March 6, 2012Publication date: August 2, 2012Applicant: TransTech Pharma, Inc.Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
-
Patent number: 8148413Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.Type: GrantFiled: September 30, 2010Date of Patent: April 3, 2012Assignee: TransTech Pharma, Inc.Inventors: Jesper Lau, Per Vedsø, János Tibor Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti, Daniel Peter Christen
-
Publication number: 20110301158Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: ApplicationFiled: August 15, 2011Publication date: December 8, 2011Applicant: Novo Nordisk A/SInventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce-Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M.M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
-
Patent number: RE45183Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: July 12, 2013Date of Patent: October 7, 2014Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsoe, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh
-
Patent number: RE45670Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: December 20, 2013Date of Patent: September 15, 2015Assignee: NOVO NORDISK A/SInventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper F. Lau, Paw Bloch, Mustafa Guzel, Santhosh Chidambareswaran Kalpathy, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen, Jesper Lau